VIRX: Viracta Therapeutics Price/Earnings to Growth Multiple
The valuation-to-earnings growth ratio demonstrates growth potential within the viral lymphoma niche, where no analogs exist. The current metric is 0.00. The success of Viracta Therapeutics (VIRX) is based on qualified personnel and an ethical approach. However, development depends on FDA verdicts and grant funding. This chart helps compare the issuer's market value with its earnings growth rate.
Viracta Therapeutics (VIRX) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
VIRX - Net Profit|Future Profit Viracta Therapeutics|VIRX - Price to Earnings Ratio|Market Cap to Future Earnings Ratio viracta.com|VIRX - PEG Multiple|EV/EBITDA Multiple Viracta|VIRX - Operating profit before deduction of amortization|Earnings per share for the trailing year Viracta Therapeutics|VIRX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months viracta.com|VIRX - Earnings growth in current year|Expected earnings per share trend next year Viracta Therapeutics
- total revenue and sales volume data:
General company analysis:VIRX, Viracta Therapeutics Inc.
Institutional investors evaluate Viracta Therapeutics (VIRX) through the lens of business scaling efficiency, where the development of complex climate logistics for drugs directly impacts future profits. By analyzing the PEG ratio trend, which compares market value to net income dynamics, one can identify asset undervaluation and avoid value traps, thereby confirming the company's fundamental stability.
Competitors of Viracta Therapeutics
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|Price/Earnings to Growth Multiple DCTH (Delcath Systems, Inc.)|Price/Earnings to Growth Ratio YMAB (ymabs.com)|PEG Multiple AURA (Aura Biosciences)|Growth-Adjusted Market Cap to Net Income Candel Therapeutics Inc. (CADL)|ARAY - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio SLS (SELLAS Life Sciences)|ACTU: PEG Multiple|citiusonc.com (CTOR) - PEG Multiple|HURA (TuHURA Biosciences Inc.) - PEG Multiple|Price/Earnings to Growth Multiple Protara Therapeutics Inc (TARA)|Price/Earnings to Growth Multiple FATE (Fate Therapeutics Corp)|Company Value to Earnings Growth Ratio WHWK|PEG Multiple TCRX (TScan Therapeutics, Inc.)|PEG Multiple Champions Oncology Inc CSBR|XBIT: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio CVM (CEL-SCI Corporation)|OSTX (OS Therapies Inc) - Price/Earnings to Growth Multiple|RADX: Company Value to Earnings Growth Ratio|ARTV (Artiva Biotherapeutics Inc.) - PEG Multiple|ANL: Growth-Adjusted Payback Ratio|PEG Multiple VERU|TPST - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Xilio Therapeutics XLO|Growth-Adjusted Payback Ratio RENB|Mural Bio - PEG Multiple|KAPA - PEG Multiple|onkuretherapeutics.com (OKUR) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio GDTC (CytoMed Therapeutics Limited)|CRIS (Curis Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Apollomics Corp APLM|Price/Earnings to Growth Multiple THAR (Tharimmune, Inc.)|PEG Multiple advanbiomed.com (ADVB)|Genprex - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio CLDI (Calidi Biotherapeutics Inc.)|Sunshine Biopharma - PEG Multiple|Growth-Adjusted Market Cap to Net Income Xenetic Biosciences XBIO|SLRX: PEG Multiple|Price/Earnings to Growth Multiple purple-biotech.com|Price/Earnings to Growth Ratio American Oncology Network Inc|BeiGene Ltd. (BGNE) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple CKPT (Checkpoint Therapeutics, Inc)|Price/Earnings to Growth Ratio ELEV (Elevation Oncology Inc.)|PEG Multiple ICAD (iCAD)|Growth-Adjusted Market Cap to Net Income Ikena Oncology Inc. (IKNA)|NTBL - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio MOR (MorphoSys Inc)|NAYA (NAYA Bio) - Price/Earnings to Growth Multiple|Growth-Adjusted P/E Ratio AAPGV
